Third-line therapy for chronic myeloid leukemia: current status and future directions

Jorge Cortes, Fabian Lang

Research output: Contribution to journalReview articlepeer-review

44 Scopus citations


Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome. The BCR-ABL1 fusion protein is an optimal target for tyrosine kinase inhibitors (TKIs) that aim for the adenosine triphosphate (ATP) binding site of ABL1. While these drugs have greatly improved the prognosis for CML, many patients ultimately fail treatment, some requiring multiple lines of TKI therapy. Mutations can occur in the ATP binding site of ABL1, causing resistance by preventing the binding of many of these drugs and leaving patients with limited treatment options. The approved TKIs are also associated with adverse effects that may lead to treatment discontinuation in some patients. Efficacy decreases with each progressive line of therapy; data suggest little clinical benefit of treatment with a third-line (3L), second-generation tyrosine kinase inhibitor (2GTKI) after failure of a first-generation TKI and a 2GTKI. Novel treatment options are needed for the patient population that requires treatment in the 3L setting and beyond. This review highlights the need for clear guidelines and new therapies for patients requiring 3L treatment and beyond.

Original languageEnglish (US)
Article number44
JournalJournal of Hematology and Oncology
Issue number1
StatePublished - Dec 2021


  • Chronic myeloid leukemia
  • Emerging therapies
  • Third line
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Third-line therapy for chronic myeloid leukemia: current status and future directions'. Together they form a unique fingerprint.

Cite this